1 Min Read
July 19 (Reuters) - CASSIOPEA SPA:
* CASSIOPEA ANNOUNCES TOP LINE POSITIVE PROOF OF CONCEPT PHASE II RESULTS FOR CB-06-02 IMMUNE MODULATOR IN TREATING GENITAL WARTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.